Aztreonam

證據等級: L5

預測適應症: 10 個

Aztreonam: From Gram-Negative Bacterial Infections to Gonococcal Urethritis

One-Sentence Summary

Aztreonam is a monobactam β-lactam antibiotic with a narrow spectrum exclusively targeting gram-negative bacteria, originally used for serious infections including urinary tract infections, lower respiratory tract infections, septicemia, and intra-abdominal infections. Among 10 TxGNN-predicted new indications evaluated in this multi-indication report, gonococcal urethritis emerges as the sole clinically actionable prediction, supported by 1 completed Phase 2/3 clinical trial (NCT03867734) and 8 publications — the remaining 9 predictions are currently rated Hold due to absent evidence or fundamental mechanistic contradictions.

Quick Overview

Item	Content
Original Indication	Serious gram-negative bacterial infections (UTI, lower respiratory tract, septicemia, intra-abdominal, skin/soft tissue)
Top TxGNN-Scored Prediction	Hyperamylasemia (Score 99.73%, Rank #5294)
Primary Actionable Prediction	Gonococcal urethritis (Score 99.59%, Rank #7243)
Evidence Level	L2 — gonococcal urethritis (1 Phase 2/3 trial + 8 publications)
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails (gonococcal urethritis only); Hold for all other 9 predictions

Prediction Landscape Summary (All 10 Indications)

Rank	Indication	TxGNN Score	Evidence Level	Recommendation	Key Issue
1	Hyperamylasemia	99.73%	L5	Hold	No trials or literature; indirect relevance only
2	Polyclonal hyperviscosity syndrome	99.73%	L5	Hold	Causal chain too indirect; no clinical basis
3	Congenital analbuminemia	99.69%	L5	Hold	Genetic disorder; no biological plausibility
4	Ureaplasma urethritis	99.59%	L5	Hold	⚠️ Fundamental mechanistic contradiction: Ureaplasma lacks a cell wall; Aztreonam has no target
5	Gonococcal urethritis	99.59%	L2	Proceed with Guardrails	1 Phase 2/3 trial + 8 publications; strongest evidence
6	Blood group incompatibility	99.59%	L5	Hold	Immune mechanism; sole literature is a false association
7	Premalignant hematological disease	99.54%	L5	Hold	Clonal disorder; antibiotic has no disease-modifying role
8	Epiglottitis	99.53%	L4	Research Question	One 1986 paediatric case series; limited and non-specific
9	Monoclonal gammopathy	99.50%	L4	Hold	Sole literature addresses haematology patients with infections, not the disease itself
10	Xanthogranulomatous pyelonephritis (XGP)	99.49%	L5	Research Question	Biologically plausible but surgery-dominant; no comparative trial

Why is This Prediction Reasonable?

Mechanism of Action

Detailed mechanism of action data for Aztreonam is not available from the Evidence Pack (Data Gap: DG002). Based on established pharmacological knowledge, Aztreonam is a monobactam antibiotic that selectively inhibits Penicillin-Binding Protein 3 (PBP3) of gram-negative bacteria, disrupting cell wall synthesis and leading to bacterial lysis. Its unique structural feature — a monocyclic β-lactam ring — confers minimal cross-reactivity with penicillins and cephalosporins, making it an important option for patients with severe β-lactam allergy.

Link Between Original and Predicted Indication

Neisseria gonorrhoeae is a gram-negative diplococcus — precisely within Aztreonam’s antibacterial spectrum. The biological rationale is direct: Aztreonam binds PBP3 of N. gonorrhoeae, inhibiting cell wall synthesis and exerting bactericidal activity. This is not an indirect extrapolation but a class-level mechanistic match.

Clinical Urgency Strengthens the Case

The prediction gains further weight from a public health imperative. The CDC has designated antimicrobial-resistant N. gonorrhoeae as one of the nation’s top three urgent antimicrobial resistance threats. Since the 1930s, gonococci have developed resistance to every first-line antibiotic in succession — sulfonamides, penicillin, tetracyclines, fluoroquinolones, and now with emerging resistance to third-generation cephalosporins (ceftriaxone). Aztreonam’s status as a non-routinely-used agent means selective pressure for resistance has been minimal, making repurposing not only biologically rational but strategically valuable as a resistance-sparing alternative.

Clinical Trial Evidence (Gonococcal Urethritis)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03867734	Phase 2/3	Completed	32	Open-label demonstration study of Aztreonam for pharyngeal gonorrhoea — the most treatment-refractory site. Single-dose intramuscular Aztreonam 2 g evaluated in men. Pharyngeal gonorrhoea was the primary focus given historically poor eradication rates at this anatomic site. Completed September 2019.

Note: Pharyngeal gonorrhoea represents the highest unmet need among gonococcal infection sites; the choice of this endpoint reflects the greatest clinical challenge.

Literature Evidence (Gonococcal Urethritis)

PMID	Year	Type	Journal	Key Findings
33077658	2020	Open-label Clinical Trial	Antimicrobial Agents and Chemotherapy	Single-arm trial of single-dose IM Aztreonam 2 g (Apr–Sep 2019); evaluated eradication of N. gonorrhoeae including pharyngeal infections; confirmed efficacy against modern strains. Core contemporary evidence.
11406757	2001	Microbiological Surveillance	J Infect Chemother	Emergence of high-level cephem- and Aztreonam-resistant N. gonorrhoeae without β-lactamase production in Japan; important resistance signal requiring monitoring.
3157346	1985	Clinical Study	Antimicrobial Agents and Chemotherapy	Aztreonam 1 g IM vs. spectinomycin 2 g IM for uncomplicated gonorrhoea; no treatment failures in either arm (urethral n=26, rectal n=3, endocervical n=3); established single-dose efficacy.
3095216	1986	Clinical Study	Genitourinary Medicine	Aztreonam 1 g IM single dose cleared infection at all sites in 61 men and 26 women, except one pharyngeal case; effective against both penicillin-sensitive and resistant strains; well tolerated.
6225808	1983	Clinical Study	J Infectious Diseases	Early demonstration of Aztreonam efficacy against penicillinase-producing N. gonorrhoeae (PPNG) at a time when treatment options were scarce; established foundational evidence.
6438364	1984	Bacteriological & Clinical Evaluation	Jpn J Antibiotics	30 male patients with gonococcal urethritis; 61 strains tested (15% PPNG); bacteriological and clinical outcomes reported; documented activity against both PPNG and non-PPNG strains.
3937450	1985	Epidemiological/Therapeutic Study	Acta Urologica Japonica	One-shot Aztreonam therapy in gonococcal infections; 244 clinical strains assessed, 17.2% PPNG; epidemiological analysis of patient demographics and outcomes.
6226596	1983	Clinical Study	Giornale Italiano di Dermatologia	Early Italian clinical study of Aztreonam in acute gonococcal urethritis; confirms early European clinical experience.

India Market Information

Aztreonam is currently not marketed in India. No drug registrations are on file.

This represents both a regulatory challenge and an opportunity: if evidence for gonococcal urethritis repurposing proceeds, a new drug application pathway will be required. The absence of existing market presence eliminates concerns about label confusion but requires a full regulatory submission.

Safety Considerations

Detailed product warnings and contraindications are not available from the Evidence Pack (Data Gap: DG001). Please refer to the originator package insert for complete safety information.

Drug Interactions (27 interactions identified via DDInter):

Clinically notable interactions include:

Interacting Drug	Interaction Level	Clinical Relevance
Warfarin	Moderate	Monitor INR; Aztreonam may potentiate anticoagulant effect
Dicoumarol	Moderate	Same mechanism as Warfarin interaction; monitor closely
Picosulfuric acid	Moderate	Monitor for additive effects; clinical significance uncertain

The remaining 24 interactions are classified as Unknown severity. Drugs involved include Vancomycin, Fluconazole, Tacrolimus, Metronidazole, Amikacin, Amphotericin B, Dexamethasone, Hydrocortisone, Ondansetron, Morphine, and others commonly co-administered in hospital settings. The Unknown classification reflects insufficient interaction data rather than confirmed safety, and clinicians should exercise standard monitoring in complex regimens.

Conclusion and Next Steps

Decision: Proceed with Guardrails (Gonococcal Urethritis)

Rationale: Gonococcal urethritis is the only indication among 10 TxGNN predictions with actionable clinical evidence: a completed Phase 2/3 trial (NCT03867734) and 8 publications spanning 1983–2020 collectively demonstrate efficacy of single-dose IM Aztreonam against N. gonorrhoeae, including modern strains and the clinically challenging pharyngeal site. The biological rationale is unambiguous (gram-negative cell wall target), and the public health urgency of multidrug-resistant gonorrhoea provides strong motivation for development.

Decision: Hold (All Other 9 Indications)

Rationale: The top TxGNN-ranked indication (hyperamylasemia, score 99.73%) and 8 of the remaining predictions lack any supporting clinical evidence. Critically, Ureaplasma urethritis (rank #4, score 99.59%) contains a fundamental mechanistic contradiction — Ureaplasma organisms have no cell wall and are intrinsically resistant to all β-lactam antibiotics including Aztreonam — demonstrating a known limitation of graph-neural-network predictions that do not encode mechanism-level constraints.

To proceed with gonococcal urethritis repurposing, the following is needed:

Safety data: Retrieve and review the full package insert (warnings, contraindications) from the originator label to complete the S1 safety screening (Data Gap DG001 — Blocking)
MOA confirmation: Formally document Aztreonam PBP3-binding mechanism via DrugBank API query (Data Gap DG002)
NCT03867734 full results: Obtain published or grey-literature results from the 2019 pharyngeal gonorrhoea trial; the PMID 33077658 publication likely constitutes these results but cross-verification is needed
Resistance monitoring: Evaluate current local N. gonorrhoeae susceptibility data for Aztreonam (reference: PMID 11406757 documents high-level resistance emergence in Japan)
Regulatory pathway: Consult CDSCO on the pathway for a new indication registration given zero existing India market presence
Formulation assessment: Confirm intramuscular formulation availability and supply chain, as all efficacy data use IM administration (1–2 g single dose)

⚠️ YMYL Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All predictions are generated by computational models (TxGNN) and must be interpreted in the context of established clinical pharmacology and regulatory requirements.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.